Literature DB >> 10483388

The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone.

G Lurcott1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 10483388      PMCID： PMC2148980     

Source DB:  PubMed          Journal:  Anesth Prog        ISSN： 0003-3006


× No keyword cloud information.
  7 in total

Review 1.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.

Authors:  M Eichelbaum; A S Gross
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

2.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.

Authors:  S V Otton; M Schadel; S W Cheung; H L Kaplan; U E Busto; E M Sellers
Journal:  Clin Pharmacol Ther       Date:  1993-11       Impact factor: 6.875

4.  The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model.

Authors:  J Cleary; G Mikus; A Somogyi; F Bochner
Journal:  J Pharmacol Exp Ther       Date:  1994-12       Impact factor: 4.030

Review 5.  Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

6.  Inhibition by fluoxetine of cytochrome P450 2D6 activity.

Authors:  S V Otton; D Wu; R T Joffe; S W Cheung; E M Sellers
Journal:  Clin Pharmacol Ther       Date:  1993-04       Impact factor: 6.875

7.  The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man.

Authors:  S Kobayashi; S Murray; D Watson; D Sesardic; D S Davies; A R Boobis
Journal:  Biochem Pharmacol       Date:  1989-09-01       Impact factor: 5.858
  7 in total
  4 in total

Review 1.  Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications.

Authors:  Karin C Söderberg Löfdal; Marine L Andersson; Lars L Gustafsson
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

2.  Trick or treat: the effect of placebo on the power of pharmacogenetic association studies.

Authors:  Clara Singer; Iris Grossman; Nili Avidan; Jacques S Beckmann; Itsik Pe'er
Journal:  Hum Genomics       Date:  2005-03       Impact factor: 4.639

3.  Preclinical and Clinical Pharmacology of Hydrocodone for Chronic Pain: A Mini Review.

Authors:  Luigi Cardia; Gioacchino Calapai; Domenico Quattrone; Cristina Mondello; Vincenzo Arcoraci; Fabrizio Calapai; Carmen Mannucci; Epifanio Mondello
Journal:  Front Pharmacol       Date:  2018-10-01       Impact factor: 5.810

Review 4.  Testosterone deficiency in non-cancer opioid-treated patients.

Authors:  F Coluzzi; D Billeci; M Maggi; G Corona
Journal:  J Endocrinol Invest       Date:  2018-10-20       Impact factor: 4.256
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.